AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RACE ONCOLOGY LTD

2.790

-0.050-1.76%

Volume:85.70K

Turnover:240.17K

Market Cap:504.39M

PE:-100.36

High:2.900

Open:2.900

Low:2.750

Close:2.840

52wk High:4.900

52wk Low:0.920

Shares:180.79M

Float Shares:121.21M

Volume Ratio:0.51

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.028

EPS(LYR):-0.028

ROE:-27.89%

ROA:-15.63%

PB:31.50

PE(LYR):-100.49

Loading ...

Overview Company News Filings

ASX Penny Stocks To Watch In December 2025

Simply Wall St.

Race Oncology Changes Name to Racura Oncology

MT Newswires Live

BRIEF-Race Oncology Completes A$3.22 Mln Private Placement

BUZZ-Australia's Race Oncology advances on premium placement

Race Oncology Ltd - Completes a$3.22M Private Placement at Issue Price of a$2.83 per New Share

THOMSON REUTERS

Race Oncology Secures Human Research Ethics Committee Approval for Non-Small Cell Lung Cancer Therapy Candidate Clinical Trial, Shares Fall 8%

MT Newswires Live

Race Oncology Ltd-Replacement Constitution

THOMSON REUTERS

Race Oncology to Launch Clinical Trials for Leukemia, Lung Cancer Therapy Candidate; Shares Jump 6%

MT Newswires Live

Race Oncology Ltd-Race Clinical Program Update

THOMSON REUTERS

ASX Opportunities: 3 Penny Stocks With Market Caps Over A$400M

Simply Wall St.

Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter

MT Newswires Live

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours

Race Oncology (ASX:RAC): Evaluating Valuation After Breakthrough Discovery in Cancer Therapy Mechanism

Simply Wall St.

Race Oncology Discovers Anticancer Activity of Bisantrene

MT Newswires Live

Korean Banks Could Face Capitalization Decline Under Looser Regulations, S&P Says

MT Newswires Live

BRIEF-Race Oncology Obtains RC220 IND Approval From Korean MFDS

Race Oncology Secures IND Approval for Cancer Drug Candidate in South Korea; Shares Up 8%

MT Newswires Live

Race Oncology Ltd - Rc220 Ind Approval From Korean Mfds

THOMSON REUTERS

Are Race Oncology's (ASX:RAC) New Bisantrene Patents a Turning Point for Its Competitive Edge?

Simply Wall St.

ASX Biggest Gainers

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":2.79,"timestamp":1766466720000,"preClose":2.84,"halted":0,"volume":85697,"delay":0,"nameEN":"RACE ONCOLOGY LTD","floatShares":121205750,"shares":180786237,"eps":-0.0278,"marketStatus":"Closed","change":-0.05,"latestTime":"12-23 16:12:00 AEDT","open":2.9,"high":2.9,"low":2.75,"amount":240174,"amplitude":0.052817,"askPrice":2.9,"askSize":5500,"bidPrice":2.79,"bidSize":1216,"shortable":3,"etf":0,"ttmEps":-0.0278,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1766530800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":2.84,"openAndCloseTimeList":[[1766444400000,1766466000000]],"volumeRatio":0.50963,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":121205750,"roa":"-15.63%","roe":"-27.89%","lyrEps":-0.027765,"volumeRatio":0.50963,"shares":180786237,"dividePrice":0,"high":2.9,"amplitude":0.052817,"preClose":2.84,"low":2.75,"week52Low":0.92,"pbRate":"31.50","psRate":"83.47","week52High":4.9,"institutionHeld":0,"latestPrice":2.79,"committee":-0.63788,"eps":-0.0278,"divideRate":0,"volume":85697,"delay":0,"ttmEps":-0.0278,"open":2.9,"prevYearClose":1.35,"prevWeekClose":2.71,"prevMonthClose":2.85,"prevQuarterClose":3.13,"fiveDayClose":2.58,"twentyDayClose":2.91,"sixtyDayClose":3.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592944597","title":"ASX Penny Stocks To Watch In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2592944597","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592944597?lang=en_us&edition=fundamental","pubTime":"2025-12-18 03:02","pubTimestamp":1765998124,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a mixed landscape with sectors like Materials showing strength while Energy struggles, investors are keenly observing potential opportunities. Penny stocks, though an older term, still represent an intriguing area of investment by highlighting smaller or less-established companies that may offer value. By focusing on those with robust financials and clear growth prospects, investors can uncover promising opportunities in this niche segment.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-chn/chalice-mining-shares/news/asx-penny-stocks-to-watch-in-december-2025-8","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-chn/chalice-mining-shares/news/asx-penny-stocks-to-watch-in-december-2025-8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7095","BK7111","BK7503","UOS.AU","BK7143","BK7104","XJO.AU","EDU.AU","BK7506","GWA.AU","BK7508","AAL.AU","CHN.AU","EZZ.AU","BK7055","IGL.AU","XKO.AU","MTO.AU","BK7012","BK7121","WAF.AU","BK7016","BK7077","BK7048","XAO.AU","PPS.AU","RAC.AU","DSK.AU","SSM.AU","BK7067","BK7132","BK7128","BK7045"],"gpt_icon":0},{"id":"2590439796","title":"Race Oncology Changes Name to Racura Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2590439796","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590439796?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:21","pubTimestamp":1765261262,"startTime":"0","endTime":"0","summary":"Race Oncology  said that following a shareholder approval at its annual general meeting held on Monday, its name will change from Race Oncology to Racura Oncology, according to a Tuesday Australian bourse filing.This change has been recorded by the Australian Securities and Investments Commission  with effect from Dec .5, the filing added.The Australian Securities Exchange  will implement the change of name from the start of trading on Wednesday, while the ASX listing code \"RAC\" remains the same, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASX","RAC.AU","ASIC","ASX.AU","BK4526","BK4107","BK7039","BK7508","BK7067","BK4141","XKO.AU","XJO.AU","BK4543","XAO.AU"],"gpt_icon":0},{"id":"2590793367","title":"BRIEF-Race Oncology Completes A$3.22 Mln Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590793367","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590793367?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:54","pubTimestamp":1765241689,"startTime":"0","endTime":"0","summary":"BRIEF-Race Oncology Completes A$3.22 Mln Private PlacementDec 9 (Reuters) - Race Oncology Ltd RAC.AX:COMPLETES A$3.22M PRIVATE PLACEMENT AT ISSUE PRICE OF A$2.83 PER NEW SHAREFurther company coverage: RAC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2590364731","title":"BUZZ-Australia's Race Oncology advances on premium placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590364731","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590364731?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:58","pubTimestamp":1765238338,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Race Oncology advances on premium placement** Shares of Race Oncology RAC.AX rise as much as 10.1% to A$2.94, their largest intraday pct jump since November 17. ** Biopharmaceutical firm receives commitments to raise A$3.22 million  via a placement. ** Placement issue price at A$2.83 per share, a 6% premium to stock's last close. ** Says funds will be used to advance the commencement of co's HARNESS-1 phase 1 trial for non-small cell lung cancer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE17Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2590236606","title":"Race Oncology Ltd - Completes a$3.22M Private Placement at Issue Price of a$2.83 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590236606","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590236606?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:59","pubTimestamp":1765231198,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2586866362","title":"Race Oncology Secures Human Research Ethics Committee Approval for Non-Small Cell Lung Cancer Therapy Candidate Clinical Trial, Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586866362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586866362?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:42","pubTimestamp":1764121361,"startTime":"0","endTime":"0","summary":"Race Oncology  received human ethics approval from the St. Vincents Hospital, Melbourne human research ethics committee to begin a phase 1a/b clinical trial assessing the safety, tolerability and pharmacokinetics of its RC220 therapy candidate, in combination with osimertinib, in patients with non-small cell lung cancer that have activating epidermal growth factor receptor mutations, according to a Wednesday Australian bourse filing.Phase 1a will begin with a circulating tumor DNA screening stage, followed by dose escalation, where between 12 and 40 patients will receive intravenous infusion of RC220 on the first day of a 21-day cycle in combination with standard-of-care osimertinib. The study will start with three single-patient cohorts before transitioning to a larger number of patient cohorts to identify the maximum tolerated dose of RC220.In the Phase 1b stage, 40 patients will be randomized to one of two treatment dose levels.Monash Health in Victoria will start enrolling patients","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC.AU","BK7067"],"gpt_icon":0},{"id":"2585437206","title":"Race Oncology Ltd-Replacement Constitution","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585437206?lang=en_us&edition=fundamental","pubTime":"2025-11-24 11:56","pubTimestamp":1763956598,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUE3S1NXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","RAC.AU"],"gpt_icon":0},{"id":"2584804690","title":"Race Oncology to Launch Clinical Trials for Leukemia, Lung Cancer Therapy Candidate; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584804690","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584804690?lang=en_us&edition=fundamental","pubTime":"2025-11-17 09:55","pubTimestamp":1763344502,"startTime":"0","endTime":"0","summary":"Race Oncology (ASX:RAC) said it will launch new clinical trials for its RC220 therapy candidate in acute myeloid leukemia and non-small cell lung cancer, according to a Monday Australian bourse filing","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2584696759","title":"Race Oncology Ltd-Race Clinical Program Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584696759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584696759?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:12","pubTimestamp":1763331145,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nTUEBRCZJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2583469589","title":"ASX Opportunities: 3 Penny Stocks With Market Caps Over A$400M","url":"https://stock-news.laohu8.com/highlight/detail?id=2583469589","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583469589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:02","pubTimestamp":1762974138,"startTime":"0","endTime":"0","summary":"The Australian market saw a flattish green day, with the ASX200 inching up by one-tenth of a percent as investors remained cautious amidst ongoing global economic uncertainties and fluctuating commodity prices. In such conditions, discerning investors often seek opportunities in lesser-known segments like penny stocks, which despite their outdated moniker, continue to offer intriguing prospects for growth. These stocks typically represent smaller or newer companies that can combine attractive...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-wia/wia-gold-shares/news/asx-opportunities-3-penny-stocks-with-market-caps-over-a400m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-wia/wia-gold-shares/news/asx-opportunities-3-penny-stocks-with-market-caps-over-a400m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IGL.AU","BK7143","BK7508","STK.AU","BK7077","BK7067","BK7016","BK7055","MTO.AU","FWD.AU","XAO.AU","SSM.AU","BK7088","BK7503","WAF.AU","LBL.AU","MXI.AU","BK7128","AAL.AU","DSK.AU","XJO.AU","XKO.AU","BK7014","WIA.AU","BK7104","BK7506","PPS.AU","BK7045","BK7095","RAC.AU"],"gpt_icon":0},{"id":"2579848629","title":"Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2579848629","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579848629?lang=en_us&edition=fundamental","pubTime":"2025-10-31 09:49","pubTimestamp":1761875382,"startTime":"0","endTime":"0","summary":"Race Oncology  said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2575576206","title":"TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=2575576206","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575576206?lang=en_us&edition=fundamental","pubTime":"2025-10-16 09:43","pubTimestamp":1760579038,"startTime":"0","endTime":"0","summary":"TrivarX has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics.Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging  equipment to visualise and monitor tumour growth without the need for radiation or surgical procedures.The platform – which utilises stable isotope labelling to identify replicating cells within the brain – will allow TrivarX to advance a targeted opportunity in the high-growth global market for brain imaging with a key focus on safety, precision and treatment monitoring.TrivarX will receive assistance from Nucleics founder Dr Daniel Tillett, who has offered to provide ongoing support and technical advice around preclinical and clinical studies.Dr Tillett is a prominent biotechnology entrepreneur, investor, and innovator with more than 25 years’ ex","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/TrivarX-ASX-TRI-Acquire-Stabl-Im-Diagnostic-Technology-Early-Detection-Metastatic-Brain-Tumours.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/TrivarX-ASX-TRI-Acquire-Stabl-Im-Diagnostic-Technology-Early-Detection-Metastatic-Brain-Tumours.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/trivarx-to-acquire-stabl-im-diagnostic-technology-for-early-detection-of-metastatic-brain-tumours/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/trivarx-to-acquire-stabl-im-diagnostic-technology-for-early-detection-of-metastatic-brain-tumours/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["MRI.AU","BK7057","BK7094","BK7508","BK7067","RAC.AU","TRI.AU"],"gpt_icon":0},{"id":"2573660905","title":"Race Oncology (ASX:RAC): Evaluating Valuation After Breakthrough Discovery in Cancer Therapy Mechanism","url":"https://stock-news.laohu8.com/highlight/detail?id=2573660905","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573660905?lang=en_us&edition=fundamental","pubTime":"2025-10-05 02:20","pubTimestamp":1759602017,"startTime":"0","endTime":"0","summary":"Race Oncology (ASX:RAC) is drawing fresh attention after revealing a breakthrough discovery on how its leading drug, bisantrene, fights cancer. This scientific milestone highlights new prospects for targeted therapies and business growth.\nSee our latest analysis for Race Oncology.\nFollowing the news of this breakthrough, Race Oncology shares saw strong momentum, briefly surging nearly 30% over the week. While recent excitement has moderated, the company’s total shareholder return of over 1%...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/race-oncology-asxrac-evaluating-valuation-after-breakthrough","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/race-oncology-asxrac-evaluating-valuation-after-breakthrough","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7508","RAC.AU","RAC"],"gpt_icon":0},{"id":"2572356911","title":"Race Oncology Discovers Anticancer Activity of Bisantrene","url":"https://stock-news.laohu8.com/highlight/detail?id=2572356911","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572356911?lang=en_us&edition=fundamental","pubTime":"2025-10-02 08:01","pubTimestamp":1759363274,"startTime":"0","endTime":"0","summary":"Race Oncology  said scientific activities carried out by the firm and its collaborators identified the anticancer activity of (E,E)-bisantrene drug candidate, according to a Thursday Australian bourse filing.Bisantrene's activity predominantly results from binding and stabilizing of regulatory DNA and RNA structures called G-quadruplexes found throughout the human genome, sequences of which form three-dimensional structures that regulate the expression and translation of many genes involved in causing cancer, including the master cancer growth regulator, MYC.Studies conducted by Race found that potent downregulation of the MYC gene occurs shortly after treatment with bisantrene, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2571382351","title":"Korean Banks Could Face Capitalization Decline Under Looser Regulations, S&P Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2571382351","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571382351?lang=en_us&edition=fundamental","pubTime":"2025-09-29 18:48","pubTimestamp":1759142938,"startTime":"0","endTime":"0","summary":"Korean banks will see weaker capitalization under looser regulatory risk-weight requirements, S&P Global Ratings said in a Monday release.Government efforts to boost banks' corporate financing, such as venture capital investments and allotment to a proposed state-led national growth fund, could increase their exposure to equities and funds, the rating agency said.These measures could dampen the banks' risk-adjusted capital  ratios, with potential downgrades for those with greater risk exposures, according to S&P.The rating agency still expects banks to continue exhibiting modest growth appetite given US trade volatility and parent groups' efforts for higher shareholder payouts.A 10% rise in equity and fund holdings would result in a modest decline in top banks' capitalization, while a doubling of this figure could lead to their average RAC ratio dropping to 7.3%, S&P said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC","BK7067","RAC.AU"],"gpt_icon":0},{"id":"2569723166","title":"BRIEF-Race Oncology Obtains RC220 IND Approval From Korean MFDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2569723166","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569723166?lang=en_us&edition=fundamental","pubTime":"2025-09-24 09:40","pubTimestamp":1758678015,"startTime":"0","endTime":"0","summary":"BRIEF-Race Oncology Obtains RC220 IND Approval From Korean MFDSSept 24 (Reuters) - Race Oncology Ltd RAC.AX:RC220 IND APPROVAL FROM KOREAN MFDSFurther company coverage: RAC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nFWN3VA0N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2569740112","title":"Race Oncology Secures IND Approval for Cancer Drug Candidate in South Korea; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569740112","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569740112?lang=en_us&edition=fundamental","pubTime":"2025-09-24 08:44","pubTimestamp":1758674653,"startTime":"0","endTime":"0","summary":"Race Oncology  said South Korea's Ministry of Food and Drug Safety  approved the investigational new drug application  to evaluate the safety, tolerability, and pharmacokinetics of the company's cancer drug candidate RC220 in combination with doxorubicin in solid tumor patients, subject to minor updates of the trial protocol, according to a Wednesday Australian bourse filing.The approval has been granted following a review of the chemistry, manufacturing, and controls, as well as nonclinical and clinical data packages for RC220, the filing added.The company said the approval enables patient recruitment at four sites in South Korea, with local ethics approval received.The company's shares rose 8% in recent Wednesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK7508","RAC.AU","BK7067","IND.AU"],"gpt_icon":0},{"id":"2569744346","title":"Race Oncology Ltd - Rc220 Ind Approval From Korean Mfds","url":"https://stock-news.laohu8.com/highlight/detail?id=2569744346","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569744346?lang=en_us&edition=fundamental","pubTime":"2025-09-24 06:58","pubTimestamp":1758668303,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nFWN3VA0N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2569735812","title":"Are Race Oncology's (ASX:RAC) New Bisantrene Patents a Turning Point for Its Competitive Edge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2569735812","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569735812?lang=en_us&edition=fundamental","pubTime":"2025-09-22 01:26","pubTimestamp":1758475566,"startTime":"0","endTime":"0","summary":"Earlier this week, Race Oncology announced a scientific discovery regarding the composition of the chemotherapy drug Bisantrene and has filed three patent applications based on these findings.\nThis move highlights the company’s continued research efforts to strengthen its intellectual property protection in the oncology treatment space.\nWe’ll explore how Race Oncology’s patent applications on new Bisantrene discoveries may influence its investment narrative and future opportunities.\nFind...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/are-race-oncologys-asxrac-new-bisantrene-patents-a-turning-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/are-race-oncologys-asxrac-new-bisantrene-patents-a-turning-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TPB","RAC.AU","RAC","BK4075","BK7067","BK7508"],"gpt_icon":0},{"id":"2568280740","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2568280740","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568280740?lang=en_us&edition=fundamental","pubTime":"2025-09-19 09:34","pubTimestamp":1758245658,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Friday.1414 Degrees : +178%, AU$0.05Swift Networks Group : +157%, AU$0.018Advance Metals : +50%, AU$0.081Kula Gold : +47%, AU$0.022Cauldron Energy : +32%, AU$0.015Noviqtech : +28%, AU$0.032C29 Metals : +25%, AU$0.03Streamplay Studio : +22%, AU$0.011Burgundy Diamond Mines : +18%, AU$0.023Race Oncology : +17%, AU$3.00","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVQ.AU","KGD.AU","BK7104","SW1.AU","BK7083","BK7035","BK7508","CXU.AU","BK7016","RAC.AU","BK7023","14D.AU","BDM.AU","AVM.AU","BK7129","SP8.AU","BK7095","BK7011","BK7067","C29.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}